Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document C2016/034/08

Prior notification of a concentration (Case M.7746 — Teva/Allergan Generics) (Text with EEA relevance)

OJ C 34, 29.1.2016, p. 16–16 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

29.1.2016   

EN

Official Journal of the European Union

C 34/16

Prior notification of a concentration

(Case M.7746 — Teva/Allergan Generics)

(Text with EEA relevance)

(2016/C 34/08)

1.

On 21 January 2016, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Teva Pharmaceutical Industries Limited (‘Teva’, Israel) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of parts of Allergan plc (‘Allergan Generics’, Ireland), by way of purchase of shares and assets.

2.

The business activities of the undertakings concerned are:

—

Teva is an Israel-headquartered global pharmaceutical company, listed on the New York Stock Exchange and the Tel Aviv Stock Exchange. Teva specialises in the development, manufacturing, marketing, sale and distribution of generic and proprietary pharmaceutical products as well as biopharmaceuticals and active pharmaceutical ingredients worldwide,

—

Allergan Generics comprises the global generics business of Allergan plc, an Ireland-headquartered global pharmaceutical company, including the United States and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, the global generic R&D unit, the international OTC commercial unit (excluding OTC eye care products) and some established international brands.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7746 — Teva/Allergan Generics, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

Top